Representing 18%-19% growth compared to first quarter 2024 revenue. The strong growth experienced in the first quarter of 2025 was driven by orthobiologics and licensing revenue.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XTNT:
- Xtant Medical Faces Risk of Share Distribution by Major Stakeholder, Threatening Stock Stability
- Xtant Medical’s Earnings Call: Mixed Outlook with Growth Plans
- Xtant Medical price target lowered to $2 from $3 at BTIG
- Xtant Medical Reports Strong 2024 Revenue Growth
- XTNT Earnings this Week: How Will it Perform?